Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2157-2162

  Xu, Jia Li ^a   Wang, Zhen Wu ^b   Hu, Ling Min ^a   Yin, Zhi Qiang ^c   Huang, Ming De ^a   Hu, Zhi Bin ^a   Shen, Hong Bing ^a   Shu, Yong Qian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Department of Radiation   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

AKT, mTOR; Chemotherapy; NSCLC; PI3K; Polymorphism; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; MTOR PROTEIN, HUMAN; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TAXOID; VINBLASTINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TOR SERINE-THREONINE KINASES; VINBLASTINE;

EID: 85047688996     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2157     Document Type: Article

References (39)

1. Alessi DR, James SR, Downes CP, et al (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol, 7, 261-9.
2. Balsara BR, Pei J, Mitsuuchi Y, et al (2004). Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis, 25, 2053-9.
3. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005). Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res, 94, 29-86.
4. Brognard J, Clark AS, Ni Y, Dennis PA (2001). Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 61, 3986-97.
5. Chen M, Cassidy A, Gu J, et al (2009). Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis, 30, 2047-52.
6. Chen M, Gu J, Delclos GL, et al (2010). Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis, 31, 1387-91.
7. Conde E, Angulo B, Tang M, et al (2006). Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res, 12, 710-7.
8. David O (2001). Akt and PTEN: new diagnostic markers of non-small cell lung cancer? J Cell Mol Med, 5, 430-3.
9. David O, Jett J, LeBeau H, et al (2004). Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res, 10, 6865-71.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.
11. Gagnon V, Van Themsche C, Turner S, et al (2008). Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis, 13, 259-71.
12. Han S, Khuri FR, Roman J (2006). Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res, 66, 315-23.
13. Hildebrandt MA, Yang H, Hung MC, et al (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol, 27, 857-71.
14. Kartalou M, Essigmann JM (2001). Mechanisms of resistance to cisplatin. Mutat Res, 478, 23-43.
15. Kim JG, Chae YS, Sohn SK, et al (2010). Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. Oncology, 79, 278-82.
16. Kim SH, Juhnn YS, Song YS (2007). Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci, 1095, 82-9.
17. Kokubo Y, Gemma A, Noro R, et al (2005). Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer, 92, 1711-9.
18. Koutros S, Schumacher FR, Hayes RB, et al (2010). Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res, 70, 2389-96.
19. Le Chevalier T (2010). Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Annals of Oncology, 21, vii196.
20. Lee S, Choi EJ, Jin C, Kim DH (2005). Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol, 97, 26-34.
21. Lin J, Wang J, Greisinger AJ, et al (2010). Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila), 3, 505-17.
22. Liu LZ, Zhou XD, Qian G, et al (2007). AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res, 67, 6325-32.
23. Marsit CJ, Zheng S, Aldape K, et al (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76.
24. Massion PP, Taflan PM, Shyr Y, et al (2004). Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med, 170, 1088-94.
25. Mungamuri SK, Yang X, Thor AD, Somasundaram K (2006). Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res, 66, 4715-24.
26. Naruke T, Tsuchiya R, Kondo H, Asamura H (2001). Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg, 71, 1759-64.
27. Pu X, Hildebrandt MA, Lu C, et al (2010). PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer, 71, 82-8.
28. Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-79.
29. Singhal S, Amin KM, Kruklitis R, et al (2003). Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther, 2, 566-71.
30. Slattery ML, Herrick JS, Lundgreen A, et al (2010). Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis, 31, 1604-11.
31. Soria JC, Lee HY, Lee JI, et al (2002). Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res, 8, 1178-84.
32. Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92.
33. Spiro SG, Silvestri GA (2005). The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med, 11, 287-91.
34. Subramanian A, Tamayo P, Mootha VK, et al (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA, 102, 15545-50.
35. Tang JM, He QY, Guo RX, Chang XJ (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51, 181-91.
36. Tee AR, Fingar DC, Manning BD, et al (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA, 99, 13571-6.
37. Tsurutani J, Fukuoka J, Tsurutani H, et al (2006). Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol, 24, 306-14.
38. Vandenbroucke E, De Ryck F, Surmont V, van Meerbeeck JP (2009). What is the role for surgery in patients with stage III non-small cell lung cancer? Curr Opin Pulm Med, 15, 295-302.
39. Wojtalla A, Arcaro A (2011). Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol, 80, 278-90